-
Photocure ASA – Notice of the annual general meeting 27 April 2017Oslo, 6 April 2017: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 27 April 2017 at 17:00 hours (CET).06 Apr 2017
-
Photocure provides strategic update• Following non-conclusive partnering discussions, the company will assess further strategic alternatives for Cevira and Visonac • Company still to focus on urology franchise, with continued commitment to driving growth in United States05 Apr 2017
-
Hexvix® featured during the 2017 annual EAU congressOslo, Norway, March 29, 2017, Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLC™) with Hexvix® was featured during the European Association of Urology (EAU) annual meeting held in London, UK, March 24th - 28th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists from over 110 countries.29 Mar 2017
-
Results for fourth quarter and full year 2016Oslo, Norway, 15 February 2017: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016 (Q4 2015: NOK 34.5), with an EBITDA of NOK 10.7 million for the Hexvix/Cysview commercial franchise. Full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.15 Feb 2017
-
A better future for patients with bladder cancer using advanced technologies includes a vital role for Blue Light Cystoscopy with Hexvix®/Cysview®Oslo, Norway, February 8th 2017, Photocure ASA announced today a publication in the Scandinavian Journal of Urology, describing a vision for improving outcomes for patients with non-muscle-invasive bladder cancer (NMIBC), and the significant role that blue light cystoscopy (BLC) with Hexvix® plays in achieving it.08 Feb 2017
-
Presentation of the fourth quarter and full year 2016 resultsPhotocure will present its fourth quarter and full year 2016 report on Wednesday 15 February 2017 at Hotel Continental, Oslo, Norway.07 Feb 2017
-
Photocure Completes Enrollment in US Market expansion study of Blue Light Flexible Cystoscopy (BLFC) with Cysview®Oslo, Norway, February 3, 2017 Photocure ASA (OSE: PHO), announced today that it has completed enrollment in its Phase 3 study with BLFC with Cysview in patients with Non Muscle Invasive Bladder cancer (NMIBC) undergoing follow up (surveillance) cystoscopy in the outpatient setting. The enrollment of 300 bladder cancer patients has secured that a minimum of 100 patients have been referred to and received repeat administrations of Blue Light Cystoscopy with Cysview in the operating room setting. In the study, Cysview was used in conjunction with the flexible KARL STORZ system. Results from the study are expected to be available mid-2017.03 Feb 2017
-
Innovative Technology Designation for Blue Light CystoscopyBlue Light equipment supplier and Photocure partner KARL STORZ Endoscopy-America, Inc. announced its system for performing Blue Light Cystoscopy with Cysview® (BLCC) has received an Innovative Technology designation from Vizient, Inc.11 Jan 2017
-
Photocure to present at investor meetings in San FranciscoPhotocure ASA (OSE: PHO) management is this week conducting investor meetings in San Francisco (US) in connection with the J.P. Morgan healthcare conference.09 Jan 2017
-
US registry shows that Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® leads to improved detection and classification of bladder cancerOslo, Norway, December 5, 2016 Photocure ASA (PHO-NO) announced today new data from a prospective multicenter real world study that included 338 patients, 415 BLC procedures and 1060 lesions from nine study sites in the United States. BLCC as an adjunct to white light cystoscopy (WLC) resulted in the detection of an additional 151 lesions and 45 patients uniquely with the addition of blue light. This resulted in upgrading or upstaging of 52 (15%) of the patients. Correct staging and grading impacts the management of bladder cancer patients and may have an impact on patient outcomes.05 Dec 2016
-
Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® decreases the risk of progression and recurrence in bladder cancerOslo, Norway, November 28th, 2016 Photocure ASA announced the publication of The Comparative effectiveness of fluorescence cystoscopy versus white light cystoscopy (WLC) for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis in the Journal of Urology. This review, which was sponsored by the US Agency for Healthcare Research (AHRQ), concluded that Blue Light Cystoscopy with Cysview®/Hexvix® was associated with decreased risk of progression and recurrence of non-muscle invasive bladder cancer versus White Light Cystoscopy alone.28 Nov 2016
-
Update on management shareholdings and exercise of employee shareUpdate on management shareholdings and exercise of employee share options in Photocure ASA ("the Company").24 Nov 2016
-
Company research report from Edison
Edison Group, an investment intelligence firm, has published a company research report on Photocure Q3 2016 results.
22 Nov 2016 -
Report from Edison21 Nov 2016
-
Results for third quarter 2016Oslo, Norway, 15 November 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 (Q3 2015: NOK 27.0) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 8.0 million.15 Nov 2016
-
Presentation of the third quarter 2016 resultsPhotocure will present its third quarter report on Tuesday 15 November 2016 at Hotel Continental, Oslo, Norway.10 Nov 2016
-
New data presented on Blue Light Cystoscopy with Cysview®/Hexvix® at the Société Internationale d'Urologie (SIU) 2016 Annual meetingOslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d'Urologie (SIU) Annual meeting, October 20th to 23rd, Buenos Aires, Argentina: an ePoster from a US registry study and an ePoster video on Blue Light Flexible Cystoscopy.25 Oct 2016